Generic drugs are the fastest growing segment fueling the growth of Antihyperlipidemic Drugs Market
Antihyperlipidemic Drugs Market |
Market Overview:
The global Antihyperlipidemic
Drugs Market is estimated to be valued at US$
13.6 Bn in 2023 and is expected to exhibit a CAGR of 7.5% over the forecast period 2023 to 2030, as
highlighted in a new report published by Coherent Market Insights.
Antihyperlipidemic drugs are
commonly known as lipid lowering drugs or statins which reduce cholesterol and
triglyceride levels in the blood. These drugs are mainly used to treat high
cholesterol levels and associated conditions like atherosclerosis, angina etc.
The drugs work by inhibiting an enzyme called HMG-CoA reductase which is
crucial for cholesterol synthesis in the liver.
Market key trends:
One of the major trends witnessed
in the antihyperlipidemic drugs market is the rising dominance of generic
drugs. Currently, generic drugs account for over 80% of the overall drugs used
for lowering lipids. Their significantly lower costs compared to branded
counterparts has made them an attractive option for patients. Various
blockbuster statins have come off patent in recent years allowing other companies
to manufacture affordable generic versions. This has paved way for greater
accessibility and adoption of anti-cholesterol medications globally.
Segment Analysis
The global antihyperlipidemic
drugs market is broadly segmented into statins, non-statins, and combination
therapies. Statins currently dominate the market as these are the most commonly
prescribed medications to lower LDL cholesterol. Statins such as atorvastatin,
rosuvastatin, and simvastatin account for over 50% of the antihyperlipidemic
drugs market share due to their effectiveness and availability in generic
forms.
Key Takeaways
The Global
Antihyperlipidemic Drugs Market Size is expected to witness high growth,
exhibiting CAGR of 7.5% over the
forecast period, due to increasing prevalence of cardiovascular diseases and
rising obesity rates.
Regional analysis
North America currently dominates
the antihyperlipidemic drugs market, accounting for over 40% share, due to high
awareness levels about hyperlipidemia and its treatment options. Asia Pacific
is expected to witness the fastest growth due to growing medical infrastructure
and increasing healthcare spending in emerging countries such as China and India.
Key players
Key players operating in the
antihyperlipidemic drugs market are Sanofi S.A., Pfizer Inc., Mylan N.V, Amgen
Inc., Abbvie Inc., Merck & Co., Inc., Dr. Reddys Laboratories Ltd.,
Bristol-Myers Squibb Company, AstraZeneca plc, and Daiichi Sankyo Company,
Limited, among others. Sanofi S.A. and Pfizer Inc. collectively dominate the
market with their statin drug offerings such as Lipitor and Lipicure.
Read More Insights Here
https://www.newsstatix.com/antihyperlipidemic-drugs-market-share-size-forecast-outlook-2023-2030/
Comments
Post a Comment